BRK is a non-receptor tyrosine kinase overexpressed in approximately two-thirds of breast carcinomas [56] as well as in some metastatic melanomas [57], renal carcinomas [58], and prostate cancers [57]—neoplasias in which either NonO, PSF or both have been implicated [21. This evidence concerns the gene PTK6 and metastatic melanoma.